JP2013503110A - ニューレグリンに基づく心不全の治療方法 - Google Patents

ニューレグリンに基づく心不全の治療方法 Download PDF

Info

Publication number
JP2013503110A
JP2013503110A JP2012514326A JP2012514326A JP2013503110A JP 2013503110 A JP2013503110 A JP 2013503110A JP 2012514326 A JP2012514326 A JP 2012514326A JP 2012514326 A JP2012514326 A JP 2012514326A JP 2013503110 A JP2013503110 A JP 2013503110A
Authority
JP
Japan
Prior art keywords
day
neuregulin
heart failure
protein
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2012514326A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013503110A5 (enExample
Inventor
ズホウ ミングドング
Original Assignee
ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド filed Critical ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド
Priority claimed from PCT/CN2010/000845 external-priority patent/WO2010142141A1/en
Publication of JP2013503110A publication Critical patent/JP2013503110A/ja
Publication of JP2013503110A5 publication Critical patent/JP2013503110A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V40/00—Recognition of biometric, human-related or animal-related patterns in image or video data
    • G06V40/10—Human or animal bodies, e.g. vehicle occupants or pedestrians; Body parts, e.g. hands
    • G06V40/12—Fingerprints or palmprints
    • G06V40/13—Sensors therefor
    • G06V40/1306—Sensors therefor non-optical, e.g. ultrasonic or capacitive sensing
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10N—ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10N39/00—Integrated devices, or assemblies of multiple devices, comprising at least one piezoelectric, electrostrictive or magnetostrictive element covered by groups H10N30/00 – H10N35/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Human Computer Interaction (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Multimedia (AREA)
  • Theoretical Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2012514326A 2009-06-09 2010-06-12 ニューレグリンに基づく心不全の治療方法 Abandoned JP2013503110A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN200910057390 2009-06-09
US23684909P 2009-08-25 2009-08-25
US61/236,849 2009-08-25
PCT/CN2010/000845 WO2010142141A1 (en) 2009-06-09 2010-06-12 Neuregulin based methods for treating heart failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015192453A Division JP6096262B2 (ja) 2009-08-25 2015-09-30 ニューレグリンに基づく心不全の治療方法

Publications (2)

Publication Number Publication Date
JP2013503110A true JP2013503110A (ja) 2013-01-31
JP2013503110A5 JP2013503110A5 (enExample) 2013-08-01

Family

ID=53673682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012514326A Abandoned JP2013503110A (ja) 2009-06-09 2010-06-12 ニューレグリンに基づく心不全の治療方法

Country Status (4)

Country Link
US (2) US9089524B2 (enExample)
JP (1) JP2013503110A (enExample)
CN (1) CN102470161A (enExample)
ES (1) ES2748886T3 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520089A (ja) * 2013-05-22 2016-07-11 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心不全を治療するためのニューレグリンの徐放
JP2022516199A (ja) * 2019-01-07 2022-02-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US20070190127A1 (en) 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
US20090156488A1 (en) * 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
BR112015006656A8 (pt) 2012-10-08 2020-01-21 Sensun Shanghai Science & Tech Co Ltd composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN105561298A (zh) * 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
AU2016375964A1 (en) * 2015-12-22 2018-05-17 Société des Produits Nestlé S.A. Methods for treating sarcopenia and frailty
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
CN117797243A (zh) * 2022-09-30 2024-04-02 上海泽生科技开发股份有限公司 神经调节蛋白及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005532332A (ja) * 2002-05-24 2005-10-27 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心血管疾患を処置するためのニューレギュリン法および組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
US20070190127A1 (en) 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
CN101394861A (zh) 2005-12-30 2009-03-25 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
EP2370093A4 (en) 2008-11-28 2012-08-29 Zensun Shanghai Science And Technology Ltd NEUREGULIN AND CARDIAC STEM CELLS
EP2808339B1 (en) 2008-11-28 2017-02-15 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin peptides and their use
EP2440236B1 (en) 2009-06-09 2016-05-04 Zensun (Shanghai) Science and Technology Limited Neuregulin based methods for treating heart failure
CA2819430C (en) 2010-12-08 2019-02-12 Unilever Plc Apparatus for the production of frozen confections
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005532332A (ja) * 2002-05-24 2005-10-27 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心血管疾患を処置するためのニューレギュリン法および組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIU,X.，ET AL.: ""Neuregulin-1/erbB-Activation Improves Cardiac Function and Survival in Models of Ischemic, Dilated", J. AM. COLL. CARDIOL., vol. No.48，No.7, JPN6014024250, 3 October 2006 (2006-10-03), pages 1438 - 1447, ISSN: 0002831042 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520089A (ja) * 2013-05-22 2016-07-11 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心不全を治療するためのニューレグリンの徐放
JP2022516199A (ja) * 2019-01-07 2022-02-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物
JP7630173B2 (ja) 2019-01-07 2025-02-17 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物

Also Published As

Publication number Publication date
ES2748886T3 (es) 2020-03-18
CN102470161A (zh) 2012-05-23
US9655949B2 (en) 2017-05-23
US20130079281A1 (en) 2013-03-28
US20160008432A1 (en) 2016-01-14
US9089524B2 (en) 2015-07-28

Similar Documents

Publication Publication Date Title
JP6266146B2 (ja) ニューレグリンに基づく心不全の治療方法
JP2013503110A (ja) ニューレグリンに基づく心不全の治療方法
JP7549907B2 (ja) 心不全の治療用組成物
EP2440236B1 (en) Neuregulin based methods for treating heart failure
JP6568052B2 (ja) 心不全を治療するためのニューレグリンの徐放
JP6475623B2 (ja) 糖尿病患者における心不全の治療用組成物
CN111407882A (zh) 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CN104436167A (zh) 神经调节蛋白用于治疗心力衰竭的有效剂量
JP2017125032A (ja) 糖尿病患者における心不全の治療用組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140910

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150930

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20151030